⌕
Altimmune · ALT · Nasdaq
Tenet 54 · Mixed
Compare
$1.56−5.17%At closeTenet 54 · Mixed
$1.56−0.09 (−5.17%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Altimmune (ALT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 99% below its peak, net margin −214861.0%. Worth your attention in FY25: Share count (+113.4%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($K)▲105.0%
41.0
FY21→FY25CAGR −68.9%/yr
Net income ($K)▲7.3%
−88,093.0
FY21→FY25CAGR —
Free cash flow ($K)▲15.4%
−67,546.0
FY21→FY25CAGR —
Diluted EPS▲25.4%
−1.00
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+113.4%

41.3mn → 88.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)41.0Revenue0.0COGS41.0Gross profit−66432.0R&D−28098.0SG&A−94489.0Op income6396.0Tax & other−88093.0Net income

-214861¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1290309677364515322580%FY21FY25

Over this window: gross 100.0% → 100.0%. Net margin -214861.0% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.4292, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
26.041.020.0426.0−68.04,410.0▲105.0%−68.9%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
26.041.020.0426.0−68.04,410.0▲105.0%−68.9%
Research & development
80,272.066,432.082,226.065,799.070,538.074,541.0▼19.2%−2.8%
Selling, general & admin
34,825.028,098.020,966.018,137.017,134.015,413.0▲34.0%+16.2%
Total operating expenses
115,097.094,530.0103,192.096,355.087,672.0101,324.0▼8.4%−1.7%
Operating incomefeeds ROC rank
−115,071.0−94,489.0−103,172.0−95,929.0−87,740.0−96,914.0▲8.4%—
Other income, net
10,717.05,715.08,113.07,482.02,830.0−176.0——
Pretax income
−104,354.0−88,774.0−95,059.0−88,447.0−84,910.0−97,090.0▲6.6%—
Income tax
—−681.00.0—−197.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−104,354.0−88,093.0−95,059.0−88,447.0−84,713.0−97,090.0▲7.3%—
Per share
Diluted EPSbuyback-sensitive
—−1.00−1.34−1.66−1.81−2.35▲25.4%—
Diluted shares (mn)
—88.1071.0053.2546.9341.28▲24.1%+20.9%
Margins
Gross margin82nd pct in Healthcare
100.0%100.0%100.0%100.0%100.0%100.0%▲0.0pp+0.0pp
Operating margin
−442580.8%−230461.0%−515860.0%−22518.5%129029.4%−2197.6%▲285399.0pp−228263.4pp
Net margin0th pct in Healthcare
−401361.5%−214861.0%−475295.0%−20762.2%124577.9%−2201.6%▲260434.0pp−212659.4pp
† TTM = trailing four quarters through 2026-09-30.
FY10 – FY20 · 11 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 11 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-06 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Altimmune's revenue last fiscal year?

Altimmune reported revenue of $41.0K in fiscal 2025, up 105.0% from fiscal 2024.

What was Altimmune's net income?

Altimmune reported net income of −$88,093.0K in fiscal 2025, a net margin of −214861.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.